ArticlePloS one2013
Beneficial effects of schisandrin B on the cardiac function in mice model of myocardial infarction.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 66 citations in OpenAlex.
- Schisandrin B confers multi-organ protection via regulation of mitochondrial homeostasis: mechanistic integration, organ-specific differences, and translational challenges-a review.Frontiers in pharmacology · 2026Review
- Review
- In vivo and in vitro investigations of schisandrin B against angiotensin II induced ferroptosis and atrial fibrosis by regulation of the SIRT1 pathway.Scientific reports · 2025Article
- Impact of Olive Oil Components on the Expression of Genes Related to Type 2 Diabetes Mellitus.Nutrients · 2025Review
- A comprehensive review of Schisandrin B's preclinical antitumor activity and mechanistic insights from network pharmacology.Frontiers in pharmacology · 2025Review
- Dibenzocyclooctadiene Lignans fromInternational journal of molecular sciences · 2024Article
- The recent advance and prospect of natural source compounds for the treatment of heart failure.Heliyon · 2024Review
- Potential traditional Chinese medicines with anti-inflammation in the prevention of heart failure following myocardial infarction.Chinese medicine · 2023Review
- Active Compounds in Fruits and Inflammation in the Body.Nutrients · 2022Review
- Lignans as Pharmacological Agents in Disorders Related to Oxidative Stress and Inflammation: Chemical Synthesis Approaches and Biological Activities.International journal of molecular sciences · 2022Review
- Ameliorative effects of Schisandrin B on Schistosoma mansoni-induced hepatic fibrosis in vivo.PLoS neglected tropical diseases · 2021Article
- The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI.Scientific reports · 2021Article
- Evaluation of the Effects ofEvidence-based complementary and alternative medicine : eCAM · 2020Article
- A Comprehensive Review on Schisandrin B and Its Biological Properties.Oxidative medicine and cellular longevity · 2020Review
- Protective effects of Salidroside on cardiac function in mice with myocardial infarction.Scientific reports · 2019Article
- Schisandrin B attenuates pressure overload-induced cardiac remodeling in mice by inhibiting the MAPK signaling pathway.Experimental and therapeutic medicine · 2019Article
- lncRNA HOTAIR Protects Myocardial Infarction Rat by Sponging miR-519d-3p.Journal of cardiovascular translational research · 2019Article
- Naturally Lignan-Rich Foods: A Dietary Tool for Health Promotion?Molecules (Basel, Switzerland) · 2019Review
- Overexpression of microRNA-202-3p protects against myocardial ischemia-reperfusion injury through activation of TGF-β1/Smads signaling pathway by targeting TRPM6.Cell cycle (Georgetown, Tex.) · 2019Article
- Analysis of Effect ofFrontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The fruit of Schisandra chinensis has been used in the traditional Chinese medicine for thousands of years. Accumulating evidence suggests that Schisandrin B (Sch B) has cardioprotection effect on myocardial ischemia in vitro. However, it is unclear whether Sch B has beneficial effects on continuous myocardial ischemia in vivo. The aim of the present study was to investigate whether Sch B could improve cardiac function and attenuate myocardial remodeling after myocardial infarction (MI) in mice. Mice model of MI was established by permanent ligation of the left anterior descending (LAD) coronary artery. Then the MI mice were randomly treated with Sch B or vehicle alone. After treatment for 3 weeks, Sch B could increase survival rate, improve heart function and decrease infarct size compared with vehicle. Moreover, Sch B could down-regulate some inflammatory cytokines, activate eNOS pathway, inhibit cell apoptosis, and enhance cell proliferation. Further in vitro study on H9c2 cells showed similar effects of Sch B on prevention of hypoxia-induced inflammation and cell apoptosis. Taken together, our results demonstrate that Sch B can reduce inflammation, inhibit apoptosis, and improve cardiac function after ischemic injury. It represents a potential novel therapeutic approach for treatment of ischemic heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.